Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 in obese patients with non-alcoholic steatohepatitis (NASH)
2017-002046-71Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in ALT at week 12. Started Oct 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2017-002046-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002046-71.